Abstract 121P
Background
Colorectal cancer (CRC) is one of the most common malignancies, which has high morbidity and mortality rates globally. Recent studies have shown that tumor immune microenvironment (TIME) plays an important role in the development of CRC. Regulatory T cells (Tregs), a group of immunosuppressive cells, is significant in TIME. However, the role of Tregs in CRC is still controversial.
Methods
We used single-cell RNA sequencing (scRNA-seq) to profile the immune landscape of CRC, aiming to identify key subtype of Treg in the TIME that contribute to the development of CRC. The role of this key subtype of Treg in CRC prognosis was investigated by survival analyses of data from The Cancer Genome Atlas (TCGA) and multiple immunohistochemistry (mIHC) data of colorectal tumor samples collected from Zhongshan Hospital of Fudan University.
Results
Through scRNA-seq of tumor lesions of 13 patients with CRC, we found a new subtype of Treg, which was presented with high expression of baculoviral IAP repeat containing 3 (BIRC3). We confirmed its existence in colorectal cancer lesions by mIHC. Survival analysis of mIHC data from Zhongshan Hospital showed that Treg with high expression of BIRC3 was related with worse overall survival (OS) in CRC patients (P = 0.015). Survival analysis of TCGA database also reached a consistent result (P = 0.024). Multivariate analyses of both mIHC and TCGA data suggested that high expression of BIRC3 in Treg cells was an independent influencing factor for OS of CRC.
Conclusions
This study reveals that BIRC3 is expressed by Treg cells. High expression of BIRC3 in Treg cells indicates negative prognosis in CRC patients, which may provide a rationale for subsequent drug development and CRC management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract